VEGFA and cancer: Due to the ability of RSV to limit production of VEGF in various models of cancer and retinal cells [8,9,10], we determined the ability of a nutraceutical, Resvega® (RSG) containing both RSV and ω3 fatty acids (EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid), to decrease the production of VEGF-A in ARPE-19, a retinal cell model spontaneously producing VEGF and mimicking the AMD phenotype [11].